Latest Breaking News On - Division of gynecologic oncology - Page 1 : comparemela.com

Jill Kolesar named next College of Pharmacy dean

Jill M. Kolesar, university research professor in the University of Kentucky College of Pharmacy and the Dr. Michael Karpf Endowed Chair in Precision Medicine, has been named dean of the University of Iowa College of Pharmacy. She will begin on July 15.

University of texasUnited statesSan antonioClark stanfordNicole brogdenDon letendreKevin kregelJillm kolesarUniversity of iowaUniversity of kentucky college medicineUniversity of texas health science centerUniversity of kentucky college pharmacyDivision of gynecologic oncologyTranslational oncology programMadison school of pharmacyUniversity of kentucky

Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

United statesDana farber cancer instituteSri lankaJoycef liuEnd results programZentalis pharmaceuticalsWomen healthHarvard medical schoolDivision of gynecologic oncologyAmerican society of clinical oncology annual meetingNational cancer institute surveillanceGynecologic oncologyDisplays preliminary efficacyClinical oncology annual meetingGynecologic oncology annual meetingCancer institute surveillance

EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors for the treatment of cancer,.

United statesPanagiotis konstantinopoulosMichael fitzhughChristopherm calabreseKevin gardnerDoug warnerLifesci communicationsProfessor of medicine at harvard medical schoolDana farber cancer instituteExchange commissionEffector therapeutics incTranslational researchDivision of gynecologic oncologyGynecologic oncologyAssociate professorHarvard medical

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesDoug warnerMichael fitzhughPanagiotis konstantinopoulosKevin gardnerChristopherm calabreseEffector therapeutics incLifesci communicationsExchange commissionDivision of gynecologic oncologyTranslational researchDana farber cancer instituteProfessor of medicine at harvard medical schoolInvestigator sponsored phaseTrial evaluating zotatifinCombination treatment

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Joycef liuHarvard medical schoolDana farber cancer instituteDivision of gynecologic oncologyGynecologic oncology